Medulloblastoma Initiative

The Medulloblastoma Initiative (MBI) is a non-profit organization dedicated to accelerating the discovery of a cure for medulloblastoma, the most common malignant brain tumor in children. The initiative functions as a collaborative research engine, funding a global consortium of world-renowned scientists and clinicians to bridge the gap between laboratory research and clinical application. By focusing on all four molecular subgroups of the disease, MBI aims to develop targeted, less toxic therapies that improve survival rates and quality of life for pediatric patients. Their strategic approach involves high-throughput drug screening, advanced genomic modeling, and the rapid translation of findings into clinical trials. MBI is powered by the Rare Cancer Research Foundation and emphasizes a transparent, data-sharing model to expedite medical breakthroughs.